Ignite Creation Date:
2025-12-25 @ 12:38 AM
Ignite Modification Date:
2025-12-25 @ 10:48 PM
Study NCT ID:
NCT00458367
Status:
COMPLETED
Last Update Posted:
2010-10-18
First Post:
2007-04-06
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
RiSPECT: Risperdal Safety Protocol Evaluation Consta Treatment, a Post Authorization Safety Survey to Obtain Information on the Safety and Efficacy of Risperidone When Used in Routine Clinical Practice
Sponsor:
Janssen Pharmaceutica N.V., Belgium
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
CR003373
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
None
Responsible Party Affiliation:
Old Name:
European Medical Affairs Director, Psychiatry
Old Organization:
Janssen-Cilag S.A., Spain